nelis h schreef op 14 december 2017 06:12:
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
Regulated information – Inside information
Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its public offering in the United States (the Offering) with anticipated gross proceeds totalling approximately $231 million from the sale of 4,440,000 American Depository Shares (ADSs), at a price to the public of $52.00 per ADS. argenx increased the Offering from the initially filed offering size of $150 million.